Compare Global E Online Ltd (GLBE) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Global E Online Ltd trades at $40.17 (market cap $6.75B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.66 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 8.7× Global E Online Ltd's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| GLBE | TAK | |
|---|---|---|
Market Cap | $6.75B | $58.74B |
Volume | 1,468,708 | 3,110,994 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $19.05 |
52-Week Low | $27.54 | $13.23 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $6.24B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $40.22, up 3.23% with strong analyst support (14 buys, 1 hold). The stock shows bullish technical momentum above key support at $40, while fundamentals reveal robust revenue growth from $962M in 2025 to $1.1B projected for 2026. Recent Q2 earnings beat expectations with 44% GMV growth, though insider selling and elevated P/E of 45.65 warrant caution.
Outlook remains positive given raised 2026 guidance and 28% upside to consensus target of $48.86. Key risks include valuation sensitivity to growth execution and persistent insider selling. The appointment of a new Chief Revenue Officer signals strategic focus on scaling, but investors should monitor quarterly execution against elevated expectations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
